A Modified R-Type Bacteriocin Specifically Targeting Clostridium difficile Prevents Colonization of Mice without Affecting Gut Microbiota Diversity
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
UNLABELLED: Clostridium difficile is a leading cause of nosocomial infections worldwide and has become an urgent public health threat requiring immediate attention. Epidemic lineages of the BI/NAP1/027 strain type have emerged and spread through health care systems across the globe over the past decade. Limiting person-to-person transmission and eradicating C. difficile, especially the BI/NAP1/027 strain type, from health care facilities are difficult due to the abundant shedding of spores that are impervious to most interventions. Effective prophylaxis for C. difficile infection (CDI) is lacking. We have genetically modified a contractile R-type bacteriocin ("diffocin") from C. difficile strain CD4 to kill BI/NAP1/027-type strains for this purpose. The natural receptor binding protein (RBP) responsible for diffocin targeting was replaced with a newly discovered RBP identified within a prophage of a BI/NAP1/027-type target strain by genome mining. The resulting modified diffocins (a.k.a. Avidocin-CDs), Av-CD291.1 and Av-CD291.2, were stable and killed all 16 tested BI/NAP1/027-type strains. Av-CD291.2 administered in drinking water survived passage through the mouse gastrointestinal (GI) tract, did not detectably alter the mouse gut microbiota or disrupt natural colonization resistance to C. difficile or the vancomycin-resistant Enterococcus faecium (VREF), and prevented antibiotic-induced colonization of mice inoculated with BI/NAP1/027-type spores. Given the high incidence and virulence of the pathogen, preventing colonization by BI/NAP1/027-type strains and limiting their transmission could significantly reduce the occurrence of the most severe CDIs. This modified diffocin represents a prototype of an Avidocin-CD platform capable of producing targetable, precision anti-C. difficile agents that can prevent and potentially treat CDIs without disrupting protective indigenous microbiota. IMPORTANCE: Treatment and prevention strategies for bacterial diseases rely heavily on traditional antibiotics, which impose strong selection for resistance and disrupt protective microbiota. One consequence has been an upsurge of opportunistic pathogens, such as Clostridium difficile, that exploit antibiotic-induced disruptions in gut microbiota to proliferate and cause life-threatening diseases. We have developed alternative agents that utilize contractile bactericidal protein complexes (R-type bacteriocins) to kill specific C. difficile pathogens. Efficacy in a preclinical animal study indicates these molecules warrant further development as potential prophylactic agents to prevent C. difficile infections in humans. Since these agents do not detectably alter the indigenous gut microbiota or colonization resistance in mice, we believe they will be safe to administer as a prophylactic to block transmission in high-risk environments without rendering patients susceptible to enteric infection after cessation of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![FIG 2 Enteric pharmacokinetics of diffocin-4 and Av-CD291.2 orally administered to mice. R-type bacteriocins that survive transit through the GI tract intact are detectable in feces by in vitro spot bioassays for bactericidal activity. Briefly, groups of 3 mice were administered diffocin-4 or Av-CD291.2 in 1% NaHCO3 (100 µg/dose [5 × 1011 KU]) via oral gavage (A) or in drinking water (60 µg/ml [3 × 1011 KU/ml]) containing 4% sucrose and 1% NaHCO3 for 28 h (B). Drinking water consumption averaged ~0.5 ml/h. Fecal pellets were collected and homogenized at the times indicated after oral gavage (A) or after introduction of Av-CD291.2 in drinking water (B). Fecal pellets collected at the indicated times were then filtered to remove microbial contaminants. The filtered homogenates were serially diluted and spotted on a soft agar lawn of the appropriately sensitive C. difficile strain R20291 (RT027). Dark zones of clearance indicate killing. Results from a representative mouse are shown for each condition.](https://figures.cochat.ai/paper-figures/df05a1dba7484e2293651275a3820e02/a-modified-r-type-bacteriocin-specifically-targeting-clostridium-difficile-figure-2.jpg)

![FIG 4 Oral administration of Av-CD291.2 in drinking water does not disturb colonization resistance to C. difficile (A) or vancomycin-resistant E. faecium (VREF) (B) in mice. Mice were administered Av-CD291.2 (2× the equivalent daily dose [mg/kg] in the microbiota study), vancomycin (37.5 mg/kg/day), or the placebo control for 4 days in the drinking water. Following a washout period, mice were inoculated with the BI/NAP1/027-type C. difficile strain or VREF C68 strain (104 CFU) by oral gavage. Fecal samples were collected on days 1, 3, 5, and 10 postinoculation and assayed for C. difficile or VREF CFU. If pathogens were not detected in stool, the lower limit of detection (2 log10 CFU/g) was assigned. The standard errors of the means (SEM) for vancomycin-treated mice are shown.](https://figures.cochat.ai/paper-figures/5799aeed973a44aebf6c5a745c6fd20a/a-modified-r-type-bacteriocin-specifically-targeting-clostridium-difficile-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the bacteriocin Avidocin-CDs, engineered to selectively target the clinically relevant C. difficile strain BI/NAP1/027, has been reported to promote pathogen clearance in mice upon oral administration.”
From Antibiotic-Induced Changes in the Intestinal Microbiota and Disease (2016) · cites this paper as [125]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Avidocin-CDs, unlike antibiotics, was not found to interfere with the ability of the microbiota to provide colonization resistance [125].”
From Antibiotic-Induced Changes in the Intestinal Microbiota and Disease (2016) · cites this paper as [125]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887 · cited 1×
“QIIME and custom scripts were used to quality filter and demultiplex the sequencing reads (60).”
Enzymatic assembly of DNA molecules up to several hundred kilobases
Gibson, D. G., Young, L., Chuang, R.-Y., Venter, J. C., Hutchison, C. A., & Smith, H. O. (2009) · Nature Methods · doi:10.1038/nmeth.1318 · Cited by 9,996 · cited 1×
“Due to the ~20-kb size, the diffocin gene cluster was cloned into the integration vector using multiple DNA fragments via the Gibson assembly method (57).”
UniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227 · cited 1×
“The unweighted UniFrac score considers only the presence or absence (incidence) of taxa (62, 63).”
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Antibiotic resistance-the need for global solutions
Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., Vlieghe, E., Hara, G. L., Gould, I. M., Goossens, H., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70318-9 · Cited by 4,439
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song, S. J., Yassour, M., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.005 · Cited by 3,220
Lozupone, C. A., Hamady, M., Kelley, S. T., & Knight, R. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.01996-06 · Cited by 2,656
Cox, L. M., Yamanishi, S., Sohn, J., Alekseyenko, A. V., Leung, J. M., Cho, I., Kim, S. G., Li, H., Gao, Z., Mahana, D., et al. (2014) · Cell · doi:10.1016/j.cell.2014.05.052 · Cited by 1,859 · cited 1×
“In spite of the extraordinary benefits of traditional antibiotics, the negative consequences of continuing to treat and mistreat bacterial diseases with antibiotics rife with off-target effects are beginning to look dire (9, 51).”
An ecological and evolutionary perspective on human–microbe mutualism and disease
Dethlefsen, L., McFall-Ngai, M., & Relman, D. A. (2007) · Nature · doi:10.1038/nature06245 · Cited by 1,660
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Cited by
Clostridium difficile infection
Smits, W. K., Lyras, D., Lacy, D. B., Wilcox, M. H., & Kuijper, E. J. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.20 · Cited by 853
Antibiotic-Induced Changes in the Intestinal Microbiota and Disease
Becattini, S., Taur, Y., & Pamer, E. G. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.04.003 · Cited by 901
“Furthermore, avidocinCDs, unlike antibiotics, was not found to interfere with the ability of the microbiota to provide colonization resistance [125].”
BackgroundMechanisms and consequences of intestinal dysbiosis
Weiss, G. A., & Hennet, T. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2509-x · Cited by 775
“difficile [187] and methicillin-resistant Staphylococcus aureus [188].”
BackgroundTargeting mechanisms of tailed bacteriophages
Nobrega, F. L., Vlot, M., de Jonge, P. A., Dreesens, L. L., Beaumont, H. J. E., Lavigne, R., Dutilh, B. E., & Brouns, S. J. J. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0070-8 · Cited by 594
Eleraky, N. E., Allam, A., Hassan, S. B., & Omar, M. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020142 · Cited by 342
“Avidocin and purocin [223] Gm+ve and Gm−ve bacteria Preclinical Modified R-type bacteriocin Novacta biosystems (NVB-302) [224] C.”
Background
Metadata
- Authors
- Gebhart, D., Lok, S., Clare, S., Tomas, M., Stares, M., Scholl, D., Donskey, C. J., Lawley, T. D., & Govoni, G. R.
- Affiliations
- AvidBiotics (United States) (US)
- Wellcome Sanger Institute (GB)
- Louis Stokes Cleveland VA Medical Center (US)
- Corresponding author
- Govoni, Gregory R.
- Venue
- mBio
- Publisher
- American Society for Microbiology
- Published
- 2015-05
- Volume
- 6
- Issue
- 2
- ISSN
- 2150-7511 (ISSN-L)
- 2161-2129
- PMC
- PMC4453579
- OpenAlex
- W2147684011
- Cited by
- 127
- References
- 64
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 10 · 2023: 11 · 2022: 12 · 2021: 12 · 2020: 9 · 2019: 6 · 2018: 14 · 2017: 12 · 2016: 16 · 2015: 7
- FWCI
- 12.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/3.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- mBio (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Wellcome Trust (WT 098051)
- National Institutes of Health (1r43ai098186-01)
- National Institute of Allergy and Infectious Diseases (1R43 AI098186, R43 AI098186)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Immunology and Microbiology › Virology › Bacteriophages and microbial interactions
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- Clostridium difficile, colonization resistance, gut microbiota, vancomycin-resistant Enterococcus faecium, antibiotic-induced dysbiosis, nosocomial infections
- MeSH terms
- Administration, Oral, Animals, Anti-Bacterial Agents, Bacteriocins, Clostridium Infections, Female, Male, Mice, Inbred C57BL, Clostridioides difficile, Gastrointestinal Tract
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Modified R-Type Bacteriocin Specifically Targeting Clostridium difficile Prevents Colonization of Mice without Affecting Gut Microbiota Diversity. https://app.cochat.ai/papers/10.1128/mbio.02368-14
- The paper
- Gebhart, D., Lok, S., Clare, S., Tomas, M., Stares, M., Scholl, D., Donskey, C. J., Lawley, T. D., & Govoni, G. R. (2015). A Modified R-Type Bacteriocin Specifically Targeting Clostridium difficile Prevents Colonization of Mice without Affecting Gut Microbiota Diversity. mBio. https://doi.org/10.1128/mbio.02368-14
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.